Kaletra and Maraviroc in Antiretroviral Therapy (ART)-Naive Patients (KALMAR Study)
Status:
Terminated
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
The primary objective of this pilot study is to assess the efficacy of lopinavir/ritonavir
(Kaletra, a protease inhibitor, PI) when used in combination with maraviroc (Selzentry, an
HIV entry inhibitor) for the treatment of antiretroviral naïve HIV infected patients. Twenty
patients will be enrolled and studied for 48 weeks.